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ABSTRACT
ObjeCtives
To examine the impact of use of rapid diagnostic tests 
for malaria on prescribing of antimicrobials, 
specifically antibiotics, for acute febrile illness in 
Africa and Asia.
Design
Analysis of nine preselected linked and codesigned 
observational and randomised studies (eight cluster or 
individually randomised trials and one observational 
study).
setting
Public and private healthcare settings, 2007-13, in 
Afghanistan, Cameroon, Ghana, Nigeria, Tanzania, and 
Uganda.
PartiCiPants
522 480 children and adults with acute febrile illness.
interventiOns
Rapid diagnostic tests for malaria.
Main OutCOMe Measures
Proportions of patients for whom an antibiotic was 
prescribed in trial groups who had undergone rapid 
diagnostic testing compared with controls and in 
patients with negative test results compared with 
patients with positive results. A secondary aim 
compared classes of antibiotics prescribed in different 
settings.
results
Antibiotics were prescribed to 127 052/238 797 (53%) 
patients in control groups and 167 714/283 683 (59%) 
patients in intervention groups. Antibiotics were 
prescribed to 40% (35 505/89 719) of patients with a 
positive test result for malaria and to 69% 
(39 400/57 080) of those with a negative result. All but 
one study showed a trend toward more antibiotic 
prescribing in groups who underwent rapid diagnostic 
tests. Random effects meta-analysis of the trials 
showed that the overall risk of antibiotic prescription 
was 21% higher (95% confidence interval 7% to 36%) 
in intervention settings. In most intervention settings, 
patients with negative test results received more 
antibiotic prescriptions than patients with positive 
results for all the most commonly used classes: 
penicillins, trimethoprim-sulfamethoxazole (one 
exception), tetracyclines, and metronidazole.
COnClusiOns
Introduction of rapid diagnostic tests for malaria to 
reduce unnecessary use of antimalarials—a beneficial 
public health outcome—could drive up untargeted use 
of antibiotics. That 69% of patients were prescribed 
antibiotics when test results were negative probably 
represents overprescription. This included antibiotics 
from several classes, including those like 
metronidazole that are seldom appropriate for febrile 
illness, across varied clinical, health system, and 
epidemiological settings. It is often assumed that 
better disease specific diagnostics will reduce 
antimicrobial overuse, but they might simply shift it 
from one antimicrobial class to another. Current global 
implementation of malaria testing might increase 
untargeted antibiotic use and must be examined.
Introduction
There is wide recognition that overuse of antimicrobials 
drives resistance in micro-organisms.1-4  Global concern 
is growing in the face of accumulating evidence show-
ing international and intercontinental spread of bacte-
rial resistance.2 3 5  Dealing this crisis has become a 
major priority, with the World Health Assembly adopt-
ing a global action plan in 2015.6  Several strategies 
have been proposed to contain the risks of antimicrobial 
WhAT IS AlReAdy knoWn on ThIS TopIC
Antimalarial drugs are widely overprescribed: introduction of rapid diagnostic tests 
for malaria reduces overprescription and helps target antimalarial drugs to those 
who need them
Antibiotics are also widely overprescribed, and antimicrobial resistance poses a 
fundamental threat to human health, development, and security
WhAT ThIS STudy AddS
At the same time as reducing overuse of antimalarial drugs, introduction of rapid 
diagnostic tests for malaria is associated with markedly increased levels of 
antibiotic prescribing especially for patients with negative test results
This effect is seen across multiple settings in Africa and Asia and, in large part, 
probably represents increased overprescribing of antibiotics
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resistance, including improved surveillance, optimised 
use of available antibiotics, development of new antibi-
otics, and development of better diagnostic tests. Tack-
ling antimicrobial resistance will require sustained 
cooperation across international borders and agencies.7 8
Across tropical and subtropical zones in Africa and 
Asia, acute febrile illness is one of the most common 
reasons for people to seek treatment from health 
 services.9  Historically, many if not most fevers have 
been considered to result from malaria and have been 
treated empirically with antimalarials.10  Many other 
infectious and non-infectious diseases, however, can 
cause similar symptoms, including bacterial and viral 
infections. Management of fever has received consider-
able attention in recent years, with widespread efforts, 
spearheaded by WHO, to improve diagnosis of malaria 
and reduce untargeted use of antimalarials.11 12  These 
efforts have relied heavily on introduction of rapid diag-
nostic tests for malaria. These tests detect parasite anti-
gen in a fingerprick blood sample and are seen as 
simple and quick to use compared with the traditional 
diagnostic method of microscopy. Each year, millions of 
rapid diagnostic tests are now used in diverse health-
care settings across endemic areas.13  In many settings 
this has led to a reduction in overprescription of anti-
malarials, but the impact on use of other treatments is 
less clear.14  There are now calls to expand disease spe-
cific rapid diagnostics as a solution to other antimicro-
bial prescribing challenges.15
We hypothesised that improved malaria diagnosis to 
reduce use of antimalarials, a widely used antimicro-
bial class, could paradoxically drive an increase in 
untargeted use of other antimicrobials, such as antibi-
otics, particularly when test results for malaria are neg-
ative.16  Little is known about the causes of non-malaria 
febrile illness in many malaria endemic countries,17 
where microbiological diagnostic facilities are limited 
or non-existent in most settings. Health workers can 
resort only to educated guesswork and empirical treat-
ment for febrile patients who do not have malaria. 
Improvements in malaria diagnosis could simply 
reduce the overuse of antimalarials, or divert overuse to 
other products like antipyretics, or it could divert anti-
malarial overuse to other antimicrobials, particularly 
antibiotics.18  Prescribing practices are not well docu-
mented or regulated in regions with little healthcare 
infrastructure and with relatively unrestricted access to 
antimicrobials.18-24  Similarly, monitoring and surveil-
lance of antimicrobial resistance is not conducted in 
most lower and middle income countries, but available 
data do show clinically relevant resistance in many 
common bacterial pathogens.25-35
The ACT Consortium (www.actconsortium.org) 
included several studies that evaluated the potential of 
rapid diagnostic tests for malaria to improve case manage-
ment for patients with undifferentiated fever in malaria 
endemic areas. Data from these studies, conducted in mul-
tiple geographical, epidemiological, and health system 
settings, provide the largest and most varied sample to 
date to assess whether changes in  antimalarial prescribing 
behaviour are associated with shifts in antibiotic prescrib-
ing. To inform policy for treatment of febrile illness, we 
compared settings where tests were and were not imple-
mented, examined the differences in antibiotic prescrib-
ing overall and by test result, and identified the antibiotic 
classes used in different settings.
Methods
Overview of studies included in analysis
The ACT Consortium conducted linked and co-designed 
research studies in Africa and Asia, including multiple 
studies designed to evaluate the impacts on healthcare 
of introducing rapid diagnostic tests for malaria in var-
ious settings. The studies were designed to be comple-
mentary and mutually reinforcing and to cover a range 
of settings. These rapid diagnostic tests were intro-
duced in various epidemiological settings and health 
service sectors (public, private retail, and community) 
and with different approaches to implementation. To 
avoid selection bias, our combined analysis includes all 
studies in the ACT Consortium that were designed a pri-
ori to test the effect of introduction of rapid diagnostic 
tests for malaria on prescribing of antimalarial drugs, 
where providers could prescribe antibiotics, and did 
not include any other studies post hoc. Detailed 
descriptions of the individual studies are available in 
open access publications.36-43
We included in the analysis studies that met the fol-
lowing criteria: evaluated an intervention to implement 
rapid diagnostic tests for malaria in settings where par-
ticipating providers could prescribe both antimalarials 
and antibiotics, compared sites with and without the 
intervention, documented prescriber behaviour as a pri-
mary outcome, and collected individual patient data on 
diagnostic test results and treatments prescribed includ-
ing antibiotics. Tables 1 and 2 present descriptions of the 
nine studies meeting these criteria. In all of the studies 
the prescribers used rapid diagnostic tests for illness 
syndromes that clinically could have been malaria.
The studies were conducted in 2007-13 in Afghani-
stan, Cameroon, Ghana, Nigeria, Tanzania, and Uganda 
in a mix of rural and urban settings. Rapid diagnostic 
tests were introduced among government sponsored 
community health workers (Afgh-com (T Leslie, et al, in 
preparation)), in public health facilities only (Afgh-
pub,36  Cam-pub,37  Ghan-pub,38  Tanz1-pub,40  Tanz2-
pub,39  Uga-pub43 ), in private drug shops only 
(Uga-priv41 ), and in a combination of public facilities, 
private pharmacies, and drug shops (Nige-mix42 ). Most 
studies included were cluster randomised trials of inter-
ventions, with the exception of two individually ran-
domised trials (Afgh-pub,36  Ghan-pub38 ), and one 
descriptive study before and after national implementa-
tion of rapid diagnostic tests (Tanz1-pub40 ). Table 2 
summarises the intervention in each study.
Microscopy services were not present or were limited 
in five study settings.36 39 41-43  In Cam-pub, microscopy 
was widely available and its use increased during the 
time of the trial alongside a national malaria 
 campaign.37  In Tanz1-pub, microscopy was available in 
some higher level facilities but was not frequently 
used.40  The two individually randomised studies (Afgh-
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com (T Leslie, et al, in preparation), Ghan-pub38) intro-
duced rapid diagnostic tests in some settings where 
routine care included microscopy. In other countries, 
the effect of introducing tests was evaluated against 
control settings where presumptive clinical diagnosis 
was the norm.
Prescribing data were collected through patient exit 
interviews or records of treatments administered 
(“ registers”) completed by the provider, both of these 
methods, and both registers and follow-up interviews 
for a subset of patients (Uga-priv).41
The main outcome of interest was the proportion of 
patients in each setting who were prescribed at least 
one systemic (oral or injectable) antibiotic. Other out-
comes included the type of antibiotic prescribed.
Patient involvement
The development of the primary research studies, from 
which these data are drawn, was informed by formative 
research among health workers, community members, and 
other stakeholders in the study settings; details for individ-
ual studies are available in open access  publications.44-47 
Results of the individual trials were disseminated to 
table 2 | Description of study designs and interventions in patients who underwent rapid diagnostic test for malaria (mrDt)
study 
abbreviation Design tests used* training† provided with test introduction in intervention settings
Afgh-com Cluster randomised trial CareStart Pf/Pan, AccessBio One day MoH training: performing mRDTs and prescribing antimalarials
Afgh-pub Individually randomised trial CareStart Pf/Pan, AccessBio One day MoH training: performing mRDTs and prescribing antimalarials
Cam-pub Cluster randomised trial SD Bioline Malaria Ag Pf/Pan, 
Standard Diagnostics
One day training: performing mRDTs, prescribing antimalarials. Enhanced training group: 
additional two day interactive training on adapting to the malaria guideline change 
including identifying major alternative causes of febrile illness, and communication skills
Ghan-pub Individually randomised trial OptiMAL-IT, Diamed AG Two day training: use of mRDTs, antimalarial prescribing, identifying major alternative 
causes of febrile illness
Tanz1-pub Baseline and follow-up 
surveys before and after mRDT 
introduction
Primarily SD Bioline Pf, 
Standard Diagnostics
Two day MoH training: performing mRDTs, prescribing antimalarials, rationale for malaria 
guideline change, identifying major alternative causes of febrile illness
Tanz2-pub Baseline survey followed by 
cluster randomised trial
Paracheck Pf, Orchid 
Biomedical Systems
Two day MoH training: performing mRDTs, prescribing antimalarials, rationale for malaria 
guideline change, identifying major alternative causes of febrile illness. Enhanced training 
group: three additional half day workshops on adapting to and sustaining guideline change, 
and communication skills
Uga-pub Cluster randomised trial Primarily SD Bioline Pf, or SD 
Bioline Pf/Pan, Standard 
Diagnostics
Two day training plus on site supervision: performing mRDTs, prescribing antimalarials, 
identifying major alternative causes of febrile illness, and communication skills
Uga-priv Cluster randomised trial First Response Ag Pf card, 
Premier Medical Corporation
Four day training: performing mRDTs, prescribing antimalarials, referral algorithm for 
mRDT-negative results, and communication skills
Nige-mix Formative study followed by 
cluster randomised trial
SD Bioline Malaria Ag Pf/Pan, 
Standard Diagnostics
Half day training: demonstration on mRDT use. Enhanced training group: additional two day 
training on performing mRDTs, prescribing antimalarials, and communication skills
MoH=Ministry of Health.
*mRDTs selected in agreement with national health authorities and supplied by studies in most cases, except in Tanz1-pub where they were supplied by MoH as part of national scale-up, and in 
Uga-pub where they were supplied by MoH with study back-up in case of stockouts of antibiotics because of intermittent supply.
†Many training programmes included information on identifying alternative causes of fever; none included systematic guidance on management of alternative causes of fever.
table 1 | Description of study contexts and populations of patients according to whether they underwent rapid diagnostic test for malaria (mrDt)
region and study abbreviation
no of patient 
encounters
Percentage (no) of 
positive test results in 
symptomatic patients* setting Healthcare sector
Median (iQr) 
patient age 
(years) study datesControl mrDt
East Afghanistan (Afgh-com/a) 607 733 28.8 (208/723) Urban and rural Community 14 (8-30) Oct 2011-May 2012
North Afghanistan (Afgh-com/b) 594 466 (1/463)
East Afghanistan (Afgh-pub/a) 2005 2048 27.1 (555/2048) Urban and rural Public 13 (7-25) Sept 2009-Sept 2010
North Afghanistan (Afgh-pub/b) 840 856 (7/856)
West Cameroon (Cam-pub/a) 400 1477 18.4 (202/1098) Urban and rural Public/mission 13 (3-29) Oct-Dec 2011
Central Cameroon (Cam-pub/b) 281 1824 50.6 (715/1412)
South east Ghana (Ghan-pub) 3634 3629 36.0 (1308/3629) Rural Public 13 (4-32) Aug 2007-Dec 2008
North Tanzania (Tanz1-pub/a) 689 750 21.4 (77/360) Rural/
peri-urban
Public 2 (1-17) May-Oct 2010; 
April-July 2012†West Tanzania (Tanz1-pub/b) 559 388 10.8 (18/167)
South east Tanzania (Tanz1-pub/c) 498 572 46.9 (192/409)
North east Tanzania (Tanz2-pub) 16 068 44 121 25.4 (4400/17 297) Rural Public 11 (2-31) Sept 2010-Jan 2011; 
Feb 2011-March 2012†
South east Uganda (Uga-pub) 210  758 221 755 69.5 (81 359/117 070) Rural Public 12 (3-28) April 2011-March 2013
South central Uganda (Uga-priv) 8109‡ 10 365‡ 57.0 (5690/9987) Rural Private retail 8 (2-22) Jan-Dec 2011
South central Nigeria (Nige-mix) 1642 4946 52.3 (589/1126) Urban and rural Public and private retail 26 (18-35) July-Dec 2009; 
June-Dec 2011†
IQR=interquartile range.
*Proportion of patients testing positive for malaria (among those in intervention settings who were tested) presented as proxy for malaria epidemiology.
†Ranges separated by semicolon indicate pre-/post- evaluations conducted before and after introduction of mRDTs. Other studies consisted of multiple study arms without (control) and with 
(intervention) mRDTs, evaluated simultaneously.
‡In Uga-priv only a subset of patients (n=497; 248 in control setting, 249 in intervention setting) were followed up after consultation to collect data on medicines prescribed.
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 participants in their local contexts. Patients were not 
directly involved in the design of the present analysis.
analysis approach
We performed three analyses to represent different policy 
and clinical perspectives. The main outcome for the first 
two analyses is the risk ratio of being prescribed at least 
one systemic (oral or injectable) antibiotic. The first anal-
ysis compared overall antibiotic prescribing for each 
study, in settings with and without rapid diagnostic test 
interventions; this represents the overall policy effect of 
introducing diagnostic tests in a given context. The sec-
ond, restricted to patients in intervention settings, looked 
at those with positive test result compared with those 
with negative results. This analysis shows the effect of test 
result on antibiotic prescribing. In the third analysis, we 
categorised prescribed antibiotics by drug class to explore 
the range of antibiotic classes used in different settings. 
We also examined the impact of rapid diagnostic tests on 
prescription of the most commonly used antibiotic 
classes, defined as those that were prescribed to at least 
5% of patients in at least one site, to see if there was a 
differential effect of test result by antibiotic class.
To allow comparison of the impact of introduction of 
rapid diagnostic tests for malaria and test results across 
studies, we calculated the risk ratios with their 95% 
confidence intervals for each study using binomial 
regression with a log link. The Huber-White robust stan-
dard error was used to account for correlation within 
the highest level of clustering (that is, within randomis-
ation clusters for the cluster randomised trials and 
within study clinics for the individually randomised 
studies).48  We carried out a random effects 
meta- analysis including all studies that compared 
groups randomised concurrently to intervention or con-
trol—that is, excluding Tanz-1, which was a before and 
after comparison, and Nige-mix and Tanz-2, which com-
pared groups randomised to interventions with pre-in-
tervention baseline data. For these three studies, table 
3 shows estimates of the impact of test introduction, but 
they do not contribute to the formal meta-analysis.
Results
Table 1 describes the study sites, including studies in 
Afghanistan (two), Cameroon, Ghana, Nigeria, Tanza-
nia (two), and Uganda (two), and covering a range of 
epidemiological settings. Data from the nine sites in six 
countries represent 522 480 patients with febrile illness 
or other malaria-like presentations.
Of patients in intervention settings for whom a 
malaria test result (slide or rapid diagnostic test) was 
available, 61 324/157 345 (39.0%) tested negative for 
malaria, ranging from 30.5% (35 711/117 070 in southeast 
Uganda) to 99.8% (462/463 in northern Afghanistan). 
Parasite prevalence acts as a proxy for local endemicity.
Table 3 shows overall data on diagnostic testing and 
antibiotic prescribing for each study setting. In interven-
tion settings, the proportion of patients for whom a test was 
performed varied from 23.1% (1137/4922) to 99.8% (724/733). 
The heterogeneity of uptake of rapid test results is import-
ant to the generalisability of these data to different settings.
antibiotic prescription in settings with and without 
interventions of rapid diagnostic tests for malaria
Antibiotics were prescribed to 127 052/238 797 (53%) 
patients in control groups and 167 714/283 683 (59%) in 
table 3 | Malaria diagnostic testing, test results, and antibiotic prescribing in control areas compared with areas where rapid diagnostic tests for 
malaria (mrDts) were introduced
study
Percentage (no) who underwent 
diagnostic test
Percentage (no) of those tested whose 
result was negative
Percentage (no) prescribed at least one 
antibiotic
risk ratio for 
antibiotic 
prescription in 
mrDt area v control 
area (95% Ci)Control* mrDt Control* mrDt Control* mrDt
Afgh-com/a 0 (0) 98.8 (724/733) 0† 71.2 (515/723) 18.2 (110/605) 54.1 (383/708) 2.98 (1.62 to 5.5)
Afgh-com/b 0 (0) 100 (466/466) 0† 99.8 (462/463) 48.4 (286/591) 68.5 (317/463) 1.41 (0.93 to 2.15)
Afgh-pub/a 100‡ (2005/2005) 100‡ (2048/2048) 67.9 (1357/2000) 72.9 (1493/2048) 38.1 (763/2005) 40.8 (836/2048) 1.07 (0.99 to 1.17)
Afgh-pub/b 55.5‡ (466/840) 100‡ (856/856) 96.6 (450/466) 99.2 (849/856) 50.6 (425/840) 70.6 (604/856) 1.39 (0.99 to 1.97)
Cam-pub/a 78.3 (313/400) 75.3 (1111/1475) 75.6 (232/307) 81.6 (896/1098) 72.8 (287/394) 78.5 (1130/1439) 1.08 (0.93 to 1.26)
Cam-pub/b 80.4 (226/281) 79.5 (1448/1822) 6.0 (13/218) 49.4 (697/1412) 50.4 (140/278) 52.1 (925/1774) 1.03 (0.66 to 1.63)
Ghan-pub 52.5‡ (1908/3634) 100‡ (3629/3629) 69.7 (1320/1907) 64.0 (2321/3629) 29.5 (1069/3623) 32.3 (1168/3615) 1.10 (0.97 to 1.24)
Tanz1-pub/a§ 7.3 (50/689) 48.4 (363/750) 50.0 (25/50) 78.6 (283/360) 29.7 (204/688) 44.7 (335/749) 1.51 (1.12 to 2.03)
Tanz1-pub/b§ 12.7 (71/559) 43.2 (167/387) 50.7 (36/71) 89.2 (149/167) 35.2 (197/559) 56.4 (219/388) 1.60 (1.27 to 2.02)
Tanz1-pub/c§ 31.3 (156/498) 71.5 (409/572) 44.9 (70/156) 53.1 (217/409) 33.1 (165/498) 49.0 (280/572) 1.48 (1.19 to 1.84)
Tanz2-pub 0 (0/16 068) 39.8¶ (17 559/44 119) 0† 74.6 (12 897/17 297) 61.5 (9875/16 068) 73.2 (32 274/44 121) 1.19 (1.13 to 1.25)
Uga-pub 7.3 (15 285/210 758) 52.9 (117 350/210 578) 41.3 (6261/15 171) 30.5 (35 711/117 070) 53.7 (113 101/ 210 758) 57.9 (128 404/221 755) 1.08 (0.90 to 1.30)
Uga-priv 0 (0/8109) 97.3 (10 078/10 365) 0† 43.0 (4297/9987) 19.4 (48/248)** 34.9 (87/249)** 1.80 (1.30 to 2.50)
Nige-mix 1.7 (27/1634) 23.1 (1137/4922) 0 (0/25) 47.7 (537/1126) 23.3 (382/1642) 15.2 (752/4946) 0.65 (0.46 to 0.93)
*Microscopy services were not present or were limited in five study settings. In Cam-pub, microscopy was widely available and its use increased during the time of the trial alongside a national 
malaria campaign. In Tanz1-pub, microscopy was available in some higher level facilities but was not frequently used. The two individually randomised studies (Afgh-com, Ghan-pub) 
introduced rapid diagnostic tests in some settings where routine care included microscopy. In other countries, the effect of introducing tests was evaluated against control settings where 
presumptive clinical diagnosis was the norm.”
†No observations (no testing available or performed in control area).
‡Afgh-pub and Ghan-pub were individually randomised trials; all patients in intervention group were tested with malaria rapid diagnostic test (mRDT); in control group, half were tested by 
microscopy, and half were diagnosed clinically.
§Tanz1 recorded medicines actually obtained by patients; other studies recorded medicines prescribed.
¶Figure is lower than that reported in primary paper39 because the present analysis included all patients with data, rather than only patients defined by study as mRDT-eligible.
**Only subset of patients (n=497) in Uga-priv followed up after consultation to collect data on medicines prescribed.
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intervention groups. The proportion of patients 
 prescribed at least one systemic (oral or injectable) anti-
biotic ranged from 18.2% (110/605) to 72.8% (287/394) in 
control settings and from 15.2% (752/4946) to 78.5% 
(1130/1439) in settings with a rapid test intervention. 
Relative to control settings, the proportion of patients 
receiving an antibiotic prescription was higher or had a 
trend towards being higher where rapid diagnostic tests 
were introduced in all but one of the studies (in Nige-
ria), with risk ratios ranging from 0.65 to 2.98 (fig 1 , and 
table 3). This represents the overall impact on health 
systems of introducing rapid diagnostic tests. A 
meta-analysis combining the randomised comparisons 
gave an overall risk ratio of 1.21 (95% confidence inter-
val 1.07 to 1.36; P=0.004)—that is, the risk of antibiotic 
prescription was 21% higher where rapid diagnostic 
tests were introduced, although there was an important 
heterogeneity between studies (I2=65%).
antibiotic prescription according to malaria 
test results
In intervention settings across all studies, antibiotic 
prescribing was higher among patients with negative 
malaria test results than among patients with positive 
results (fig 2  and table 4). Antibiotics were prescribed to 
40% (35 505/89 719) of patients with a positive test result 
and to 69% (39 400/57 080) of those with a negative 
result. Differences were substantial in several studies 
(Afgh-com/a, Afgh-pub/a and b, Cam-pub/a and b, 
Ghan-pub, Tanz1-pub/a and c, Tanz2-pub, Uga-pub and 
Uga-priv), with risk ratios overall varying from 1.13 to 
15.17. This represents the impact of health workers 
obtaining a test result negative for malaria.
types of antibiotics prescribed
Table 5  shows the percentage of patients at each site 
who were prescribed each class of antibiotic. Figure 3 
shows the percentage contribution of each antibiotic 
class to total antibiotic prescribing at each site. Penicil-
lins and trimethoprim-sulfamethoxazole (TMP-SMX, or 
cotrimoxazole) were the most commonly prescribed 
antibiotics, with metronidazole the third most 
 prescribed antibiotic at most sites. In Cam-pub, Nige-
mix, and Tanz1-pub the type of antibiotic prescribed 
was not known in 52.1% (2075/3982), 10.7% (708/6588), 
and 15.9% (548/3456) of cases, respectively, because of 
the data collection approach or coding.
Compared with patients with positive malaria test 
results, prescription of each of the four most common 
classes of antibiotic (penicillins, TMP-SMX, tetracy-
clines, and metronidazole) was higher for patients with 
negative test results across most sites (table 6). Risk 
ratios ranged from 1.70 to 28.2 for penicillins, 0.96 to 
19.7 for TMP-SMX, 3.21 to 9.0 for tetracyclines, and 1.24 
to 3.37 for metronidazole.
discussion
In this analysis of African and Asian studies including 
over half a million children and adults with acute febrile 
illness, we found that introduction of rapid diagnostic 
tests for malaria to reduce unnecessary use of antimalar-
ials—a beneficial public health outcome—could drive up 
empirical use of antibiotics. Antimicrobial drug resis-
tance can result in prolonged illnesses, higher mortality, 
and increased costs of treatment and is a major global 
concern.7  Unnecessary overuse of antimicrobials 
increases drug pressure and contributes to the develop-
ment and spread of antimicrobial resistance. Acute 
febrile illness is one of the most common presenting 
syndromes in tropical and subtropical regions, and 
patient and prescriber beliefs and behaviours regarding 
management of fever influence antimicrobial use.49 50
Several studies, including the component studies in 
our analysis, have shown that rapid diagnostic tests for 
malaria, when combined with effective training, can 
reduce overuse of antimalarials.8  Our current study, 
however, has shown that the desired reduction in empir-
ical use of antimalarial drugs was often  accompanied by 
  Cam-pub/b
  Afgh-pub/a
  Cam-pub/a
  Uga-pub
  Ghan-pub
  Afgh-pub/b
  Afgh-com/b
  Uga-priv
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Overall: P=0.004, I2=65%
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1.07 (0.99 to 1.17)
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1.10 (0.97 to 1.24)
1.39 (0.99 to 1.97)
1.41 (0.93 to 2.15)
1.80 (1.30 to 2.50)
2.98 (1.62 to 5.46)
1.21 (1.07 to 1.36)
5
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Fig 1 | risk ratios for antibiotic prescription in randomised studies comparing patients in 
control settings with patients in settings where malaria rapid diagnostic test intervention 
was implemented. Weights are from random effects analysis
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Cam-pub/b
Tanz1-pub/b
Tanz1-pub/a
Uga-pub
Uga-priv
Tanz1-pub/c
Ghan-pub
Tanz2-pub
Afgh-pub/b
Afgh-com/a
Afgh-pub/a
1.09 (0.79 to 1.49)
1.13 (1.00 to 1.26)
1.15 (0.96 to 1.37)
1.31 (0.57 to 3.04)
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1.71 (1.38 to 2.12)
1.95 (1.41 to 2.69)
2.01 (1.41 to 2.85)
2.50 (2.16 to 2.91)
2.51 (2.04 to 3.09)
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Fig 2 | risk ratios for antibiotic prescription in settings with 
malaria rapid diagnostic test intervention, comparing 
patients with positive versus negative malaria test results. 
afgh-com/b is not included because risk ratio could not be 
calculated; comparison is not possible when no patients 
with positive test results received antibiotic
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an unintended shift toward increased prescription of 
other antimicrobials, specifically antibiotics. This shift 
was observed for multiple classes of antibiotics and 
across several epidemiological and healthcare contexts 
where rapid diagnostic tests were introduced. In partic-
ular, empirical antibiotic use was much more common 
for patients with negative malaria test results. These 
findings suggest that without additional interventions, 
current major initiatives to introduce rapid diagnostic 
tests for malaria—which could effectively reduce inap-
propriate use of antimalarials and the risk of antimalar-
ial drug resistance14 —can unintentionally exchange 
presumptive overuse of antimalarials for presumptive 
overuse of antibiotics. The potential for this prescribing 
shift was recognised in the early days of increasing the 
use of these tests,16  and these concerns now seem to be 
real in many settings.18 There is a widespread assump-
tion that improving pathogen specific diagnosis with 
better tests will reduce overuse of antimicrobials, but it 
might simply shift overuse from one class to another.
strengths and weaknesses of study
The strengths of the study include the wide range of 
geographical, epidemiological, and healthcare settings 
that are typical of contexts where rapid diagnostic tests 
for malaria will be used and the consistency and size of 
the effect on antibiotic prescribing. Data from over 
520 000 patient encounters in Africa and Asia were 
available, providing the broadest sample currently 
available to evaluate shifts in prescribing behaviour 
associated with test implementation.
As with all studies there are limitations. The ACT Con-
sortium studies were conducted in sites representative 
of where most patients typically seek treatment. As 
advanced microbiology diagnostic facilities were not 
readily available at these sites, the data do not allow 
determination of whether antibiotic use was appropri-
ate for individual patients. Antibiotic availability varied 
table 4 | antibiotic prescribing by test result in areas with rapid diagnostic test for 
malaria (mrDt) intervention
study
Percentage (no) of patients prescribed at least 
one antibiotic*
risk ratio for antibiotic 
prescription for test 
negative v test positive 
patients (95% Ci)negative test result Positive test result
Afgh-com/a 72.8 (366/503) 8.1 (16/197) 9.0 (6.2 to 12.9)
Afgh-com/b 68.9 (316/459) 0 (0/1) —†
Afgh-pub/a 54.7 (816/1493) 3.6 (20/555) 15.2 (8.0 to 28.9)
Afgh-pub/b 71.0 (603/849) 14.3 (1/7) 5.0 (2.31 to 10.7)
Cam-pub/a 81.6 (718/880) 72.5 (140/193) 1.13 (1.00 to 1.26)
Cam-pub/b 58.5 (397/679) 50.9 (356/700) 1.15 (0.96 to 1.37)
Ghan-pub 41.3 (953/2310) 16.5 (215/1305) 2.50 (2.16 to 2.91)
Tanz1-pub/a‡ 53.0 (150/283) 31.6 (24/76) 1.68 (1.00 to 2.83)
Tanz1-pub/b‡ 58.4 (87/149) 44.4 (8/18) 1.31 (0.57 to 3.04)
Tanz1-pub/c‡ 61.8 (134/217) 30.7 (59/192) 2.01 (1.42 to 2.85)
Tanz2-pub 75.6 (9750/12 897) 30.1 (1326/4400) 2.51 (2.04 to 3.09)
Uga-pub 69.9 (24 963/35 711) 40.8 (33 214/81 359) 1.71 (1.38 to 2.12)
Uga-priv 46.0 (52/113) 23.6 (30/127) 1.95 (1.41 to 2.69)
Nige-mix 17.7 (95/537) 16.3 (96/589) 1.09 (0.79 to 1.49)
*Where denominators do not sum to total, uptake of mRDTs by clinicians was not 100%, so that mRDT not 
performed for proportion of patients seen.
†Comparison not possible where no mRDT-positive patients received antibiotic.
‡Tanz1 recorded drugs actually obtained by patients; other studies recorded medicines prescribed. 
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across study settings, which increases generalisability 
of the results but also means that sites are not strictly 
comparable in terms of drugs or classes used. Limita-
tions of individual studies are reported in the published 
papers on their findings.
This analysis design can robustly identify that there 
is an increase in antibiotic prescribing after introduc-
tion of rapid diagnostic tests for malaria, but it cannot 
identify the reasons for this shift at an individual pre-
scriber level. Qualitative research would be better 
suited to answer such questions.
Combination of data from studies with meta-analysis 
must be undertaken with caution when the data come 
from highly variable epidemiological settings and 
 different health settings. We therefore consider the 
summary statistic useful, but it should not be overinter-
preted, and the consistency of results across different 
settings is equally important.
There were no major outbreaks (such as the Ebola 
epidemic in West Africa) in any of the study sites that 
might have affected the results.
interpretation in light of other studies
It is not possible to know whether antibiotic prescription 
was appropriate at the individual patient level in this 
analysis because the studies did not collect full clinical 
data or samples for further laboratory investigation. In 
most similar settings where bacterial diagnosis has been 
undertaken, however, few patients have documented 
bacterial infections; fewer than 2% (and in virtually all 
reports <5%) of patients with uncomplicated febrile ill-
ness have positive results on blood  cultures.51-53  Not all 
bacterial causes of fever lead to bacteraemia, but, for 
example, in young children with uncomplicated febrile 
illness in Zanzibar, just 22% had an infection retrospec-
tively considered to require antibiotics.54 At a population 
level it is likely that relatively few patients in our studies 
had bacterial infections requiring antibiotic treatment, 
and the incidence is unlikely to be anywhere near the 
69% suggested by antibiotic prescription to those with 
negative results of malaria tests.
Case management guidelines for limited resource set-
tings, such as the WHO’s Integrated Management of 
Childhood Illness (IMCI) and Integrated Management 
of Adult and Adolescent Illness, do not recommend 
empirical use of antibiotics for non-severe febrile  illness 
Afghanistan Cameroon Ghana Nigeria
Cephalosporins Chloramphenicol Macrolides Tetracyclines Other antibiotics
Penicillins Aminoglycosides Metronidazole Antibiotic type not speciedCotrimoxazoleFluoroquinolones
Tanzania 1 Tanzania 2 Uganda public health facilities Uganda drug shop vendors
57%
7%
7%
7% 7%
7%
10%
73%
58%
36%
13%9%
9%
22%
8%
5%
51%
52%
22%
20%
38%
33% 30% 30% 30%
43%
5%
11% 11%
12%11%
15%
Fig 3 | antibiotic class as proportion of all antibiotics prescribed in each study (control and intervention settings combined). afghanistan data are from 
afgh-pub only; afgh-com health workers had access only to trimethoprim-sulfamethoxazole. White areas for Cameroon, nigeria, afghanistan, and 
tanzania-1 indicate that systemic (oral or injectable) antibiotic was prescribed but that name was not specified in study records. labels indicate classes 
that accounted for ≥5% of all antibiotics prescribed for each study
table 6 | risk ratios (95% confidence interval) for antibacterial prescription by class* for 
patients with negative v test positive test results in rapid diagnostic test for malaria 
(mrDt) intervention†
Penicillin tMP/sMX Metronidazole tetracycline
Afgh-pub 28.2 (11.5 to 69) 19.7 (7.2 to 54) 0‡ 6.5 (0.97 to 43)
Cam-pub 1.70 (1.08 to 2.69) 0.96 (0.47 to 1.94) 1.24 (0.78 to 1.97) 6.3 (0.86 to 46)
Ghan-pub 2.25 (1.72 to 2.95) 3.57 (2.30 to 5.5) 2.64 (1.55 to 4.5) 9.0 (0.94 to 87)
Tanz1-pub§ 3.21 (1.80 to 5.7) 1.32 (0.88 to 1.98) 0‡ 0‡
Tanz2-pub 3.73 (2.82 to 4.9) 1.87 (1.45 to 2.40) 2.45 (1.38 to 4.3) 3.21 (1.98 to 5.2)
Uga-pub 2.17 (1.68 to 2.80) 1.48 (1.13 to 1.95) 3.37 (2.72 to 4.2) 7.0 (4.7 to 10.5)
Uga-priv 2.00 (0.98 to 4.1) 1.43 (0.70 to 2.91) 2.47 (0.76 to 8.0) 0‡
*Penicillins primarily included oral and injectable penicillin formulations, and amoxicillin with or without 
clavulanic acid, as well as ampicillin, cloxacillin, dicloxacillin, and flucloxacillin; TMP/SMX=trimethoprim-
sulfamethoxazole; metronidazole also included secnidazole, tinidazole; tetracycline was typically doxycycline.
†Afgh-com, study among community health workers in Afghanistan, dropped from this analysis because 
trimethoprim-sulfamethoxazole was only antibiotic to which participating health workers had access. Nige-mix, 
study in Nigeria, dropped from this analysis as no or few observations in many relevant categories.
‡No or few observations in relevant categories.
§Tanz1 recorded drugs actually obtained by patients; other studies recorded medicines prescribed.
doi: 10.1136/bmj.j1054 | BMJ 2017;356:j1054 | the bmj
RESEARCH
8
of unclear aetiology.55 56  The extent to which these 
guidelines are used, or adhered to, however, varies by 
setting. Studies in settings where antibiotics are not 
available to prescribers, such as chemist shops in 
Ghana, have shown that withholding both antibiotics 
and antimalarials diverts patients to antipyretics, which 
is a safe strategy for most uncomplicated  illness.57
With declining incidence of malaria in many settings, 
the proportion of fevers attributable to illnesses other 
than malaria stands to increase. Currently rapid diag-
nostic tests are more useful to rule out malaria than to 
rule it in, at least in Africa, but this is likely to change as 
the incidence of malaria drops. As this transition occurs 
and the proportion of negative test results increases, 
the risk of inappropriate antibiotic treatment of patients 
with negative results is likely to increase as well. Wide-
spread childhood vaccination for pneumococcus, 
meningococcus, and Haemophilus influenzae type B, 
and the resulting reduction in bacteraemia and bacte-
rial infection, have further reduced the risk that 
non-specific, non-severe febrile illness is caused by a 
potentially serious bacterial pathogen in many African 
and Asian countries.58-60
Even when treatment with antibiotics is warranted, 
patients might not receive the most appropriate antibiotic 
for their illness, particularly in settings with inadequate 
healthcare infrastructure.20 In the studies we analysed, 
choice of antibacterial was inevitably untargeted as 
health workers in these settings do not have access to 
facilities to confirm diagnoses and identify pathogens nor 
to epidemiological data to help guide antibiotic choic-
es—a health system weakness that is unfortunately typi-
cal across most malaria endemic areas. In the ACT 
Consortium studies, nearly all antibiotic prescriptions 
were for penicillins, trimethoprim-sulfamethoxazole, tet-
racyclines, and, in several sites, metronidazole. The fact 
that metronidazole prescribing was more common where 
rapid diagnostic tests for malaria were introduced, simi-
lar to the pattern for other antibiotic classes, suggests a 
relatively haphazard approach to empirical prescribing; 
few causes of malaria-like febrile illness can be effectively 
treated with metronidazole.
Within each study site, different antibiotics predomi-
nated, which could reflect to varying degrees local 
availability including stockouts (when healthcare facil-
ities run out) of antibiotics because of intermittent sup-
ply,61  recommendations in national or other clinical 
guidelines such as IMCI,56  and personal or institutional 
preferences. Other broad spectrum antibiotics such as 
cephalosporins, fluoroquinolones, and macrolides 
were relatively infrequently prescribed in the sites stud-
ied and are probably either less available or affordable 
or are thought to be restricted to particular indications; 
this could change over the next few years. Of note, at 
most sites tetracyclines accounted for only a tiny frac-
tion of antibiotics prescribed, even among non-paediat-
ric patients; yet this inexpensive antibiotic class could 
be a rational empirical choice to cover zoonotic infec-
tious agents such as rickettsiae, leptospira, and several 
bacteria that cause a considerable proportion of infec-
tions in these areas.17 62-64  Reliable data on antibiotic 
resistance are scarce to non-existent in regions typified 
by ACT Consortium study sites20; reports that are avail-
able from Africa indicate that, for example, currently 
1% to 100% of Streptococcus pneumoniae isolates are 
resistant to penicillin, while 0% to 35% isolates 
of  non-typhoidal salmonella are resistant to 
 fluoroquinolones.65
Clinical case management typically follows an 
expected pathway that culminates in the prescription or 
purchase of medicines.66 67  In low resource settings, 
antimicrobial medicines are often the cornerstone of 
care.68 69  Presentation of fever is expected to result in 
antimicrobial prescription.49 70 71  Behaviour change to 
reduce unnecessary overuse of antimalarials can occur 
when introduction of diagnostic technologies is accom-
panied by a well designed and implemented pro-
gramme of training and supervision.37 39  41
Meaning of study for policy and clinical practice
This analysis suggests that while introduction of rapid 
diagnostic tests for malaria can reduce untargeted 
excessive use of antimalarials—a highly beneficial pub-
lic health outcome across malaria endemic regions—it 
can also have the unintended consequence of driving up 
untargeted and probably excessive use of antibiotics. In 
this analysis, the shift included antibiotics from several 
classes and was consistent across nearly all the varied 
clinical and epidemiological settings studied, increas-
ing the generalisability of the findings. Therefore when 
rapid diagnostic tests are introduced, policymakers and 
clinicians should avoid a switch to overuse of antibiot-
ics, a concern that increases the challenges of changing 
prescribing practice. This awareness is important in the 
design of programmes for provider training and commu-
nity education in Africa and Asia, where antibiotic use is 
already relatively unregulated and unrestricted.20 24 65 
Without thoughtful intervention in the near term, as the 
burden of malaria declines and negative malaria test 
results become more common, the trend toward com-
pensatory prescription of antibiotics can only contribute 
to increasing levels of antibiotic resistance.
unanswered questions and future research
This analysis shows quantitatively that introduction of 
rapid diagnostic tests for malaria can lead to an increase 
in antibiotic prescribing in many settings. Two major 
gaps in evidence need to be filled to inform policy and 
clinical practice guidelines to deal with this problem. 
The first is to identify the current drivers of this pre-
scribing behaviour (mainly with qualitative research 
but also with epidemiology) to inform efforts toward 
behaviour change. The second, especially important for 
the rational revision of diagnostic algorithms such as 
IMCI, is to identify the treatable or preventable causes 
of non-malaria febrile illness (mainly with microbiol-
ogy, virology, and epidemiology).
autHOr aFFiliatiOns
1London School of Hygiene and Tropical Medicine, London WC1E 
7HT, UK
2Ghana Health Service, Accra, Ghana
the bmj | BMJ 2017;356:j1054 | doi: 10.1136/bmj.j1054
RESEARCH
9
3Ensign College of Public Health, Kpong, Ghana
4University of California, San Francisco, CA, USA
5Karolinska Institutet, Stockholm, 17176, Sweden
6University of Gothenburg, Gothenburg, Sweden
7University of Copenhagen, Copenhagen, DK1014, Denmark
8US Centers for Disease Control and Prevention, Atlanta, GA, USA
9Liverpool School of Tropical Medicine, Liverpool, UK
10Health Protection Research Organisation, Kabul, Afghanistan
11Centre for Medical Parasitology, University of Copenhagen and 
Copenhagen University Hospital, and Department for Veterinary 
Disease Biology, University of Copenhagen, Copenhagen, Denmark
12Uppsala University, Uppsala, Sweden
13Ministry of Health, Kampala, Uganda
14Makerere University School of Public Health, Kampala, Uganda
15Zanzibar Malaria Elimination Programme, Tanzania
16Department of Pharmacology and Therapeutics, University of 
Nigeria, Enugu, Nigeria
17Kintampo Health Research Centre, Kintampo, Ghana
18Centre for Malaria Research, Karolinska Institutet, Stockholm, 
Sweden, and Health Metrics at Sahlgrenska Academy, University of 
Gothenburg, Gothenburg, Sweden
19Department of Infectious Disease Epidemiology, Statens Serum 
Institut, Copenhagen, Denmark
20School of Public Health and Community Medicine, University of 
New South Wales, Sydney, Australia
We gratefully acknowledge the assistance of the clinical staff and 
patients in all of the studies contributing data for this analysis. We 
thank Daniel Chandramohan, Bonnie Cundill, Catherine Maiteki, 
Renata Mandike, Wilfred Mbacham, Richard Ndyomugyenyi, Denise 
Roth Allen, and Rebecca Thomson for their valuable participation in 
earlier discussions of the ACT Consortium RDTs in Context working 
group; Paul Snell for development and management of the central 
data repository; and Bianca D’Souza, Débora Miranda, Rebecca 
Tremain, Eleanor Challenger, and Philippe Verstraete for logistical and 
administrative support for this analysis.
Contributors: KJB, CIRC, EKA, FB, SC, DD, CG, SPK, SL, DGL, TL, PM, LMJ, 
IM, AKM, OEO, HR, MWR, JW, VLW, SY, DS, SGS, and CJMW contributed to 
the design and supervision and/or coordination of the nine primary 
studies on which this analysis is based. All authors participated in the 
working group that contributed to the idea, design, and interpretation 
of the analysis. KJB, BL, and HH prepared the data for analysis. KJB 
analysed the data for the main outcome measures; HH analysed the 
data for the secondary aim. MEC and BL advised on statistical analysis. 
HH and KJB had full access to all of the data in the study and take 
responsibility for the integrity of the data and the accuracy of the data 
analysis. HH and CJMW drafted the manuscript. All authors critically 
revised the manuscript for important intellectual content, and read and 
approved the final paper. HH is guarantor of the paper.
Funding: All individual studies and this analysis were supported by 
the ACT Consortium, which is funded through a grant from the Bill and 
Melinda Gates Foundation to the London School of Hygiene and 
Tropical Medicine. The study funders had no role in the study design, 
implementation, analysis, manuscript preparation, or decision to 
submit this article for publication. The findings and conclusions in this 
report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Ethical approval: All studies in this analysis had ethical approval from 
their host academic institutions and national authorities, as detailed 
in open access published reports from the individual studies.
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no 
financial relationships with any organisations that might have an interest 
in the submitted work in the previous three years; no other relationships 
or activities that could appear to have influenced the submitted work.
Transparency: The lead author affirms that the manuscript is an 
honest, accurate, and transparent account of the study being reported; 
that no important aspects of the study have been omitted; and that 
any discrepancies from the study as planned (and, if relevant, 
registered) have been explained.
Data sharing: Data from individual studies and a combined dataset 
used for this analysis are available from the ACT Consortium data 
repository (https://actc.lshtm.ac.uk/, searchable by author, publication 
date, or journal) or from the corresponding authors on request. 
Participant consent for data sharing was not obtained for all studies, 
but the presented data are anonymised and risk of identification is low.
This is an Open Access article distributed in accordance with the terms 
of the Creative Commons Attribution (CC BY 4.0) license, which 
permits others to distribute, remix, adapt and build upon this work, for 
commercial use, provided the original work is properly cited. See: 
http://creativecommons.org/licenses/by/4.0/.
1 Carattoli A. Plasmids and the spread of resistance. Int J Med 
Microbiol 2013;303:298-304. doi:10.1016/j.ijmm.2013.02.001. 
2 Manenzhe RI, Zar HJ, Nicol MP, Kaba M. The spread of 
carbapenemase-producing bacteria in Africa: a systematic review. J 
Antimicrob Chemother 2015;70:23-40. doi:10.1093/jac/dku356. 
3 Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance 
plasmids and international high-risk clones in the spread of 
multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev 
2015;28:565-91. doi:10.1128/CMR.00116-14. 
4 Oneko M, Kariuki S, Muturi-Kioi V, et al. Emergence of Community-
Acquired, Multidrug-Resistant Invasive Nontyphoidal Salmonella 
Disease in Rural Western Kenya, 2009-2013. Clin Infect Dis 
2015;61(Suppl 4):S310-6. doi:10.1093/cid/civ674. 
5 Baker KS, Dallman TJ, Ashton PM, et al. Intercontinental dissemination 
of azithromycin-resistant shigellosis through sexual transmission: a 
cross-sectional study. Lancet Infect Dis 2015;15:913-21. doi:10.1016/
S1473-3099(15)00002-X. 
6  World Health Organization. Global Action Plan on Antimicrobial 
Resistance.WHO, 2015.
7 Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need 
for global solutions. Lancet Infect Dis 2013;13:1057-98. doi:10.1016/
S1473-3099(13)70318-9. 
8 Ochodo E, Garner P, Sinclair D. Achieving universal testing for malaria. 
BMJ 2016;352:i107. doi:10.1136/bmj.i107. 
9 Crump JA, Kirk MD. Estimating the Burden of Febrile Illnesses. PLoS 
Negl Trop Dis 2015;9:e0004040. doi:10.1371/journal.pntd.0004040. 
10 Amexo M, Tolhurst R, Barnish G, Bates I. Malaria misdiagnosis: effects 
on the poor and vulnerable. Lancet 2004;364:1896-8. doi:10.1016/
S0140-6736(04)17446-1. 
11  World Health Organization. Universal access to malaria diagnostic 
testing - An operational manual.WHO, 2013.
12 Hopkins H, Asiimwe C, Bell D. Access to antimalarial therapy: accurate 
diagnosis is essential to achieving long term goals. BMJ 
2009;339:b2606. doi:10.1136/bmj.b2606. 
13  WHO. WHO Guidelines for the treatment of malaria.WHO, 2015.
14 Odaga J, Sinclair D, Lokong JA, Donegan S, Hopkins H, Garner P. Rapid 
diagnostic tests versus clinical diagnosis for managing people with fever in 
malaria endemic settings. Cochrane Database Syst Rev 2014;4:CD008998.
15 Review on Antimicrobial Resistance (chaired by Jim O'Neill). Tackling 
drug-resistant infections globally: final report and recommendations. 
AMR Review, 2016. https://amr-review.org/sites/default/
files/160518_Final%20paper_with%20cover.pdf
16 Baiden F, Webster J, Owusu-Agyei S, Chandramohan D. Would rational 
use of antibiotics be compromised in the era of test-based 
management of malaria?Trop Med Int Health 2011;16:142-4. 
doi:10.1111/j.1365-3156.2010.02692.x. 
17 Prasad N, Murdoch DR, Reyburn H, Crump JA. Etiology of Severe Febrile 
Illness in Low- and Middle-Income Countries: A Systematic Review. 
PLoS One 2015;10:e0127962. doi:10.1371/journal.pone.0127962. 
18 Ndhlovu M, Nkhama E, Miller JM, Hamer DH. Antibiotic prescribing 
practices for patients with fever in the transition from presumptive 
treatment of malaria to ‘confirm and treat’ in Zambia: a cross-sectional 
study. Trop Med Int Health 2015;20:1696-706. doi:10.1111/tmi.12591. 
19 Alsan M, Schoemaker L, Eggleston K, Kammili N, Kolli P, Bhattacharya 
J. Out-of-pocket health expenditures and antimicrobial resistance in 
low-income and middle-income countries: an economic analysis. 
Lancet Infect Dis 2015;15:1203-10. doi:10.1016/
S1473-3099(15)00149-8. 
20 Bebell LM, Muiru AN. Antibiotic use and emerging resistance: how can 
resource-limited countries turn the tide?Glob Heart 2014;9:347-58. 
doi:10.1016/j.gheart.2014.08.009. 
21 Lee AC, Chandran A, Herbert HK, et al. Treatment of infections in young 
infants in low- and middle-income countries: a systematic review and 
meta-analysis of frontline health worker diagnosis and antibiotic access. 
PLoS Med 2014;11:e1001741. doi:10.1371/journal.pmed.1001741. 
22 Ofori-Asenso R, Agyeman AA. A review of injection and antibiotic use 
at primary health care (public and private) centers in Africa. J Pharm 
Bioallied Sci 2015;7:175-80. doi:10.4103/0975-7406.160008. 
23 Yin X, Song F, Gong Y, et al. A systematic review of antibiotic utilization 
in China. J Antimicrob Chemother 2013;68:2445-52. doi:10.1093/jac/
dkt223. 
24 Mbonye AK, Buregyeya E, Rutebemberwa E, et al. Prescription for 
antibiotics at drug shops and strategies to improve quality of care and 
patient safety: a cross-sectional survey in the private sector in 
Uganda. BMJ Open 2016;6:e010632. doi:10.1136/
bmjopen-2015-010632. 
25 Ashley EA, Lubell Y, White NJ, Turner P. Antimicrobial susceptibility of 
bacterial isolates from community acquired infections in Sub-Saharan 
Africa and Asian low and middle income countries. Trop Med Int 
Health 2011;16:1167-79. doi:10.1111/j.1365-3156.2011.02822.x. 
RESEARCH
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
26 Gebrekidan A, Dejene TA, Kahsay G, Wasihun AG. Prevalence and 
antimicrobial susceptibility patterns of Shigella among acute 
diarrheal outpatients in Mekelle hospital, Northern Ethiopia. BMC Res 
Notes 2015;8:611. doi:10.1186/s13104-015-1606-x. 
27 Huynh BT, Padget M, Garin B, et al. Burden of bacterial resistance 
among neonatal infections in low income countries: how convincing 
is the epidemiological evidence?BMC Infect Dis 2015;15:127. 
doi:10.1186/s12879-015-0843-x. 
28 Kariuki S, Dougan G. Antibacterial resistance in sub-Saharan Africa: an 
underestimated emergency. Ann N Y Acad Sci 2014;1323:43-55. 
doi:10.1111/nyas.12380. 
29 Kwambana-Adams B, Darboe S, Nabwera H, et al. Salmonella 
Infections in The Gambia, 2005-2015. Clin Infect Dis 2015;61(Suppl 
4):S354-62. doi:10.1093/cid/civ781. 
30 Le Doare K, Bielicki J, Heath PT, Sharland M. Systematic Review of 
Antibiotic Resistance Rates Among Gram-Negative Bacteria in 
Children With Sepsis in Resource-Limited Countries. J Pediatric Infect 
Dis Soc 2015;4:11-20. doi:10.1093/jpids/piu014. 
31 Leopold SJ, van Leth F, Tarekegn H, Schultsz C. Antimicrobial drug 
resistance among clinically relevant bacterial isolates in sub-Saharan 
Africa: a systematic review. J Antimicrob Chemother 2014;69:2337-53. 
doi:10.1093/jac/dku176. 
32 Lubell Y, Ashley EA, Turner C, Turner P, White NJ. Susceptibility of 
community-acquired pathogens to antibiotics in Africa and Asia in 
neonates--an alarmingly short review. Trop Med Int Health 
2011;16:145-51. doi:10.1111/j.1365-3156.2010.02686.x. 
33 Lubell Y, Turner P, Ashley EA, White NJ. Susceptibility of bacterial 
isolates from community-acquired infections in sub-Saharan Africa 
and Asia to macrolide antibiotics. Trop Med Int Health 2011;16:1192-
205. doi:10.1111/j.1365-3156.2011.02837.x. 
34 Mshana SE, Matee M, Rweyemamu M. Antimicrobial resistance in 
human and animal pathogens in Zambia, Democratic Republic of 
Congo, Mozambique and Tanzania: an urgent need of a sustainable 
surveillance system. Ann Clin Microbiol Antimicrob 2013;12:28. 
doi:10.1186/1476-0711-12-28. 
35 Obeng-Nkrumah N, Labi AK, Acquah ME, Donkor ES. Bloodstream 
infections in patients with malignancies: implications for antibiotic 
treatment in a Ghanaian tertiary setting. BMC Res Notes 2015;8:742. 
doi:10.1186/s13104-015-1701-z. 
36 Leslie T, Mikhail A, Mayan I, et al. Rapid diagnostic tests to improve 
treatment of malaria and other febrile illnesses: patient randomised 
effectiveness trial in primary care clinics in Afghanistan. BMJ 
2014;348:g3730. doi:10.1136/bmj.g3730. 
37 Mbacham WF, Mangham-Jefferies L, Cundill B, et al. Basic or enhanced 
clinician training to improve adherence to malaria treatment 
guidelines: a cluster-randomised trial in two areas of Cameroon. 
Lancet Glob Health 2014;2:e346-58. doi:10.1016/
S2214-109X(14)70201-3. 
38 Ansah EK, Narh-Bana S, Epokor M, et al. Rapid testing for malaria in 
settings where microscopy is available and peripheral clinics where 
only presumptive treatment is available: a randomised controlled trial 
in Ghana. BMJ 2010;340:c930. doi:10.1136/bmj.c930. 
39 Cundill B, Mbakilwa H, Chandler CI, et al. Prescriber and patient-
oriented behavioural interventions to improve use of malaria rapid 
diagnostic tests in Tanzania: facility-based cluster randomised trial. 
BMC Med 2015;13:118. doi:10.1186/s12916-015-0346-z. 
40 Bruxvoort K, Kalolella A, Nchimbi H, et al. Getting antimalarials on 
target: impact of national roll-out of malaria rapid diagnostic tests on 
health facility treatment in three regions of Tanzania. Trop Med Int 
Health 2013;18:1269-82. doi:10.1111/tmi.12168. 
41 Mbonye AK, Magnussen P, Lal S, et al. A Cluster Randomised Trial 
Introducing Rapid Diagnostic Tests into Registered Drug Shops in 
Uganda: Impact on Appropriate Treatment of Malaria. PLoS One 
2015;10:e0129545. doi:10.1371/journal.pone.0129545. 
42 Onwujekwe O, Mangham-Jefferies L, Cundill B, et al. Effectiveness of 
Provider and Community Interventions to Improve Treatment of 
Uncomplicated Malaria in Nigeria: A Cluster Randomized Controlled 
Trial. PLoS One 2015;10:e0133832. doi:10.1371/journal.pone.0133832. 
43 Staedke SG, Maiteki-Sebuguzi C, DiLiberto DD, et al. The Impact of an 
Intervention to Improve Malaria Care in Public Health Centers on 
Health Indicators of Children in Tororo, Uganda (PRIME): A 
Cluster-Randomized Trial. Am J Trop Med Hyg 2016;95:358-67. 
doi:10.4269/ajtmh.16-0103. 
44 Achonduh OA, Mbacham WF, Mangham-Jefferies L, et al. Designing 
and implementing interventions to change clinicians’ practice in the 
management of uncomplicated malaria: lessons from Cameroon. 
Malar J 2014;13:204. doi:10.1186/1475-2875-13-204. 
45 Chandler CI, Meta J, Ponzo C, et al. The development of effective 
behaviour change interventions to support the use of malaria rapid 
diagnostic tests by Tanzanian clinicians. Implement Sci 2014;9:83. 
doi:10.1186/1748-5908-9-83. 
46 DiLiberto DD, Staedke SG, Nankya F, et al. Behind the scenes of the 
PRIME intervention: designing a complex intervention to improve 
malaria care at public health centres in Uganda. Glob Health Action 
2015;8:29067doi:10.3402/gha.v8.29067.
47 Ezeoke OP, Ezumah NN, Chandler CC, et al. Exploring health providers’ 
and community perceptions and experiences with malaria tests in 
South-East Nigeria: a critical step towards appropriate treatment. 
Malar J 2012;11:368. doi:10.1186/1475-2875-11-368. 
48 Williams RL. A note on robust variance estimation for cluster-
correlated data. Biometrics 2000;56:645-6. 
doi:10.1111/j.0006-341X.2000.00645.x. 
49 Chandler CI, Mangham L, Njei AN, Achonduh O, Mbacham WF, 
Wiseman V. ‘As a clinician, you are not managing lab results, you are 
managing the patient’: how the enactment of malaria at health 
facilities in Cameroon compares with new WHO guidelines for the use 
of malaria tests. Soc Sci Med 2012;74:1528-35. doi:10.1016/j.
socscimed.2012.01.025. 
50 McKay R, Mah A, Law MR, McGrail K, Patrick DM. Systematic Review of 
Factors Associated with Antibiotic Prescribing for Respiratory Tract 
Infections. Antimicrob Agents Chemother 2016;60:4106-18. 
doi:10.1128/AAC.00209-16. 
51 D’Acremont V, Kilowoko M, Kyungu E, et al. Beyond malaria--causes of 
fever in outpatient Tanzanian children. N Engl J Med 2014;370:809-17. 
doi:10.1056/NEJMoa1214482. 
52 Mtove G, Hendriksen IC, Amos B, et al. Treatment guided by rapid 
diagnostic tests for malaria in Tanzanian children: safety and 
alternative bacterial diagnoses. Malar J 2011;10:290. 
doi:10.1186/1475-2875-10-290. 
53 Brent AJ, Ahmed I, Ndiritu M, et al. Incidence of clinically significant 
bacteraemia in children who present to hospital in Kenya: 
community-based observational study. Lancet 2006;367:482-8. 
doi:10.1016/S0140-6736(06)68180-4. 
54 Elfving K, Shakely D, Andersson M, et al. Acute Uncomplicated Febrile 
Illness in Children Aged 2-59 months in Zanzibar - Aetiologies, 
Antibiotic Treatment and Outcome. PLoS One 2016;11:e0146054. 
doi:10.1371/journal.pone.0146054. 
55  World Health Organization. IMAI district clinician manual: Hospital 
care for adolescents and adults, Guidelines for the management of 
common illnesses with limited resources. Integrated Management of 
Adolescent and Adult Illness.IMAI, 2011.
56  World Health Organization. Integrated Management of Childhood 
Illness: Chart Booklet. WHO, 2014.
57 Ansah EK, Narh-Bana S, Affran-Bonful H, et al. The impact of providing 
rapid diagnostic malaria tests on fever management in the private 
retail sector in Ghana: a cluster randomized trial. BMJ 
2015;350:h1019. doi:10.1136/bmj.h1019. 
58 Diomandé FV, Djingarey MH, Daugla DM, et al. Public Health Impact 
After the Introduction of PsA-TT: The First 4 Years. Clin Infect Dis 
2015;61(Suppl 5):S467-72. doi:10.1093/cid/civ499. 
59 Mackenzie GA, Hill PC, Jeffries DJ, et al. Effect of the introduction of 
pneumococcal conjugate vaccination on invasive pneumococcal 
disease in The Gambia: a population-based surveillance study. Lancet 
Infect Dis 2016;16:703-11. doi:10.1016/S1473-3099(16)00054-2. 
60 Mtove G, Amos B, Nadjm B, et al. Decreasing incidence of severe 
malaria and community-acquired bacteraemia among hospitalized 
children in Muheza, north-eastern Tanzania, 2006-2010. Malar J 
2011;10:320. doi:10.1186/1475-2875-10-320. 
61  World Health Organization. The World Medicines Situation 
2011.WHO, 2011.
62 D’Acremont V, Kaiser L, Genton B. Causes of fever in outpatient 
Tanzanian children. N Engl J Med 2014;370:809-17. doi:10.1056/
NEJMoa1214482. 
63 Crump JA, Morrissey AB, Nicholson WL, et al. Etiology of severe 
non-malaria febrile illness in Northern Tanzania: a prospective cohort 
study. PLoS Negl Trop Dis 2013;7:e2324. doi:10.1371/journal.
pntd.0002324. 
64 Prabhu M, Nicholson WL, Roche AJ, et al. Q fever, spotted fever group, 
and typhus group rickettsioses among hospitalized febrile patients in 
northern Tanzania. Clin Infect Dis 2011;53:e8-15. doi:10.1093/cid/
cir411. 
65  World Health Organization. Antimicrobial resistance: global report on 
surveillance.WHO, 2014.
66 Parsons T. The Social System.Routledge & Kegan Paul, 1951.
67 Reynolds Whyte S, Hardon A. Social Lives of Medicines.Cambridge 
University Press, 2002.
68 Biehl J. Pharmaceutical Governance. In: Kleinman A, Lakoff A, 
Kleinman A, eds. Global Pharmaceuticals: Ethics, Markets, 
Practices.Duke University Press, 2006.
69 Van der Geest S, Whyte SR. The Charm of Medicines - Metaphors and 
Metonyms - Reply. Med Anthropol Q 1991;5:172-4doi:10.1525/
maq.1991.5.2.02a00050.
70 Ansah EK, Reynolds J, Akanpigbiam S, Whitty CJ, Chandler CI. “Even if 
the test result is negative, they should be able to tell us what is wrong 
with us”: a qualitative study of patient expectations of rapid 
diagnostic tests for malaria. Malar J 2013;12:258. 
doi:10.1186/1475-2875-12-258. 
71 Reynolds J, Wood M, Mikhail A, et al. Malaria “diagnosis” and 
diagnostics in Afghanistan. Qual Health Res 2013;23:579-91. 
doi:10.1177/1049732312470761. 
